Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252

Status: Closed to Accrual

Learn more:

• clinicaltrials.gov: #NCT03241186
• News release

Study Contact: studies@hoosiercancer.org; (317) 921-2050.